Skip to main content
. 2016 Dec 20;83(5):1056–1071. doi: 10.1111/bcp.13184

Table 3.

Treatment‐related adverse events in each treatment group (times)

Group Grade 1 Grade 2 Grade 3 Grade 4/5 Total
rHSA/IFNα2a 600 μg 52 (68.42) 21 (27.63) 3 (3.95) 0 (0.00) 76
rHSA/IFNα2a 750 μg 64 (66.67) 24 (25.00) 8 (8.33) 0 (0.00) 96
rHSA/IFNα2a 900 μg 85 (77.27) 23 (20.91) 2 (1.82) 0 (0.00) 110
Peg‐IFNα2a 180 μg 87 (69.05) 31 (24.60) 8 (6.35) 0 (0.00) 126